Exploring and comparing adverse events between PARP inhibitors
CJ LaFargue, GZ Dal Molin, AK Sood… - The lancet …, 2019 - thelancet.com
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted
therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of …
therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of …
Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis
KM Mustian, CM Alfano, C Heckler, AS Kleckner… - JAMA …, 2017 - jamanetwork.com
Importance Cancer-related fatigue (CRF) remains one of the most prevalent and
troublesome adverse events experienced by patients with cancer during and after therapy …
troublesome adverse events experienced by patients with cancer during and after therapy …
Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer
KC Arbour, L Mezquita, N Long, H Rizvi… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L) 1)
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …
Cancer-related fatigue, version 2.2015
AM Berger, K Mooney, A Alvarez-Perez… - Journal of the National …, 2015 - jnccn.org
Cancer-related fatigue is defined as a distressing, persistent, subjective sense of physical,
emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment …
emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment …
Cancer-related fatigue—mechanisms, risk factors, and treatments
JE Bower - Nature reviews Clinical oncology, 2014 - nature.com
Fatigue is one of the most common adverse effects of cancer that might persist for years after
treatment completion in otherwise healthy survivors. Cancer-related fatigue causes …
treatment completion in otherwise healthy survivors. Cancer-related fatigue causes …
The biology of cancer-related fatigue: a review of the literature
Purpose Understanding the etiology of cancer-related fatigue (CRF) is critical to identify
targets to develop therapies to reduce CRF burden. The goal of this systematic review was …
targets to develop therapies to reduce CRF burden. The goal of this systematic review was …
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer
S Yennurajalingam, S Frisbee-Hume… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Cancer-related fatigue (CRF) is the most common symptom in patients with
advanced cancer. The primary objective of this prospective, randomized, double-blind …
advanced cancer. The primary objective of this prospective, randomized, double-blind …
Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors
BACKGROUND The effective management of fatigue in patients with cancer requires a clear
delineation of what constitutes nontrivial fatigue. The authors defined numeric cutpoints for …
delineation of what constitutes nontrivial fatigue. The authors defined numeric cutpoints for …
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
J Bohlius, K Schmidlin, C Brillant, G Schwarzer… - The Lancet, 2009 - thelancet.com
Background Erythropoiesis-stimulating agents reduce anaemia in patients with cancer and
could improve their quality of life, but these drugs might increase mortality. We therefore did …
could improve their quality of life, but these drugs might increase mortality. We therefore did …
Erythropoietin or darbepoetin for patients with cancer
T Tonia, A Mettler, N Robert… - Cochrane database …, 2012 - cochranelibrary.com
Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …